Key facts
- ArteraAI’s last known valuation is $400.0M (Mar 2023).
- It has raised $109.5M; the latest was Early Stage VC in Aug 2025.
- Notable investors include Coatue Management, Breyer Capital, EDBI, Jeff Dean, Johnson & Johnson JJDC — 30 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 30 names
- ·Watchlist + deal alerts for ArteraAI
- ·The full record, as it builds
Funding rounds
No funding rounds for ArteraAI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArteraAI
Developer of AI-enabled predictive and prognostic cancer tests designed to identify patients who will benefit from therapy intensification. The company's tests leverage an algorithm that assesses digital images from a patient's biopsy and learns from a patient's clinical data, enabling clinicians with more information to make informed treatment decisions.
- Sector
- Healthcare
- HQ
- Los Altos, CA, United States
- Founded
- 2021
- Employees
- 136
- Website
- artera.ai/
- Ownership
- Privately Held (backing)
ArteraAI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArteraAI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArteraAI in its N-PORT filings yet. We sweep new filings monthly.